Thrombolytic therapy. From myocardial to cerebral infarction

被引：3

作者：

Candelise, L ^{[1
]}

Roncaglioni, D ^{[1
]}

Aritzu, E ^{[1
]}

Ciccone, A ^{[1
]}

Maggioni, AP ^{[1
]}

Ricci, S ^{[1
]}

Roncaglioni, MC ^{[1
]}

Tognoni, G ^{[1
]}

Wardlaw, J ^{[1
]}

机构：

[1] IST RIC FARMACOL MARIO NEGRI, MILAN, ITALY

来源：

ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES | 1996年 / 17卷 / 01期

关键词：

acute cerebral stroke; thrombolytic therapy; cerebral recanalization; myocardial infarction; TISSUE-PLASMINOGEN-ACTIVATOR; UNSTABLE ANGINA-PECTORIS; ACUTE ISCHEMIC STROKE; PLACEBO-CONTROLLED TRIAL; LEFT-VENTRICULAR FUNCTION; LOCAL INTRAARTERIAL THROMBOLYSIS; TRANSCRANIAL DOPPLER SONOGRAPHY; INTRAVENOUS STREPTOKINASE; RANDOMIZED TRIAL; EMBOLIC STROKE;

D O I：

10.1007/BF01995705

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Thrombolysis is proposed for the acute treatment of cerebral infarction as it is able to recanalize occluded arteries and thus potentially restore normal perfusion of the cerebral parenchyma, but the results concerning the efficacy of this treatment are still inconclusive. However, it has been fully demonstrated that thrombolytic treatment, leads to a significant reduction in mortality, in patients with acute myocardial infarction. Data from all of the pilot studies using SK or tPA treatment in acute stroke are described in this review, which underlines the incidence of hemorrhagic transformation (hemorrhagic infart and parenchymal hematoma) and its possible correlation to clinical worsening. Pharmacological, experimental and clinical studies encourage the carrying out of large-scale clinical trials using thrombolytics in patients with acute cerebral infarction. Significant data relating to ongoing controlled clinical trials will be available in the near future; only after the analysis of these results will it be possible to confirm the efficacy of thrombolytics in acute stroke.

引用

页码：5 / 21

页数：17

共 133 条

[51]

HACKE W, 1993, THROMBOLYTIC THERAPY, V2, P153

[52] URGENT THERAPY FOR STROKE .2. PILOT-STUDY OF TISSUE PLASMINOGEN-ACTIVATOR ADMINISTERED 91-180 MINUTES FROM ONSET [J].

HALEY, EC ;

LEVY, DE ;

BROTT, TG ;

SHEPPARD, GL ;

WONG, MCW ;

KONGABLE, GL ;

TORNER, JC ;

MARLER, JR .

STROKE, 1992, 23 (05) :641-645

[53] PILOT RANDOMIZED TRIAL OF TISSUE-PLASMINOGEN ACTIVATOR IN ACUTE ISCHEMIC STROKE [J].

HALEY, EC ;

BROTT, TG ;

SHEPPARD, GL ;

BARSAN, W ;

BRODERICK, J ;

MARLER, JR ;

KONGABLE, GL ;

SPILKER, J ;

MASSEY, S ;

HANSEN, CA ;

TORNER, JC .

STROKE, 1993, 24 (07) :1000-1004

[54]

HALL GH, 1987, LANCET, V2, P96

[55]

HAMPTON J, 1993, LANCET, V342, P759

[56]

HENDERSCHEE D, 1991, J NEUROL NEUROSUR PS, V54, P71

[57] INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR FOR THE TREATMENT OF ACUTE THROMBOEMBOLIC ISCHEMIA [J].

HENNERICI, M ;

HACKE, W ;

VONKUMMER, R ;

HORNIG, C ;

ZANGEMEISTER, W .

CEREBROVASCULAR DISEASES, 1991, 1 :124-128

[58]

HENZE T, 1987, LANCET, V2, P1391

[59]

HOLMBERG S, 1990, AM J CARDIOL, V65, P401

[60] TERMINATION OF TRIAL OF STREPTOKINASE IN SEVERE ACUTE ISCHEMIC STROKE [J].

HOMMEL, M ;

BOISSEL, JP ;

CORNU, C ;

BOUTITIE, F ;

LEES, KR ;

BESSON, G ;

LEYS, D ;

AMARENCO, P ;

BOGAERT, M .

LANCET, 1995, 345 (8941) :57-57

← 1 2 3 4 5 6 7 8 9 10 →